Chemotherapy-induced vomiting in children: some progress, more questions
Menée auprès de 502 patients atteints de cancer et âgés de moins de 17 ans, cette étude randomisée multicentrique de phase III compare l'efficacité du palonosétron et de l'ondansétron en prévention des nausées et vomissements induits par une chimiothérapie modérément ou hautement émétisante
In this issue of The Lancet Oncology, Gábor Kovács and colleagues1 report the results of their non-inferiority trial of palonosetron in paediatric patients with cancer, which prospectively assesses chemotherapy-induced nausea and vomiting in the largest group of children so far—an impressive accomplishment. This Article also provides an opportunity to discuss remaining barriers to achieving complete control of chemotherapy-induced nausea and vomiting in children including chemotherapy emetogenicity classification, definitions of acute and delayed phases, nausea assessment, and standardisation of chemotherapy-induced nausea and vomiting prophylaxis.
The Lancet Oncology , commentaire, 2015